Pharmaceutical drug
Golimumab , sold under the brand name Simponi , is a human monoclonal antibody which is used as an immunosuppressive medication .[ 3] [ 5] Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule[ 6] and hence is a TNF inhibitor . Profound reduction in C-reactive protein (CRP) levels, interleukin (IL)-6 , intercellaular adhesion molecules (ICAM)- 1, matrix metalloproteinase (MMP)-3 , and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism.[ 7] Golimumab is given via subcutaneous injection .[ 3] [ 5] [ 8]
It is on the World Health Organization's List of Essential Medicines .[ 9]
^ Mazumdar S, Greenwald D (2009). "Golimumab" . mAbs . 1 (5): 422–31. doi :10.4161/mabs.1.5.9286 . PMC 2759491 . PMID 20065639 .
^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)" . nctr-crs.fda.gov . FDA . Retrieved 22 October 2023 .
^ a b c "Simponi- golimumab injection, solution" . DailyMed . 30 September 2019. Retrieved 11 November 2020 .
^ "Simponi Aria- golimumab solution" . DailyMed . 2 October 2020. Retrieved 11 November 2020 .
^ a b c "Simponi EPAR" . European Medicines Agency (EMA) . 17 September 2018. Retrieved 11 November 2020 .
^ Statement On A Nonproprietary Name Adopted By The USAN Council – Golimumab Archived 20 February 2012 at the Wayback Machine , American Medical Association .
^ Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. (March 2014). "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update" . Annals of the Rheumatic Diseases . 73 (3): 492–509. doi :10.1136/annrheumdis-2013-204573 . PMC 4079096 . PMID 24161836 .
^ Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. (March 2014). "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update" . Annals of the Rheumatic Diseases . 73 (3): 492–509. doi :10.1136/annrheumdis-2013-204573 . PMC 4079096 . PMID 24161836 .
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) . Geneva: World Health Organization. hdl :10665/371090 . WHO/MHP/HPS/EML/2023.02.